1 **Impact of a National Immunisation Program on herpes zoster incidence in**
2 **Australia**

3

4 *Running title:* Population impact of a zoster immunisation program

5

6 Jialing Lin ^{a,*}, Timothy Dobbins ^a, James G Wood ^a, Carla Bernardo ^b, Nigel P Stocks
7 ^b, Bette Liu ^a

8

9 ^a *School of Population Health, University of New South Wales, Sydney, NSW 2052,*
10 *Australia.*

11 ^b *Discipline of General Practice, Adelaide Medical School, University of Adelaide,*
12 *Adelaide, SA 5005, Australia.*

13

14 ^{*} Corresponding author.

15 *E-mail address:* jialing.lin@student.unsw.edu.au (J. Lin).

16 **Summary**

17 *Objectives:* To evaluate the impact of the National Herpes Zoster (zoster)

18 Immunisation Program in Australia on zoster incidence.

19 *Methods:* Ecological analysis of zoster incidence related to timing of implementation
20 of the national program in vaccine-targeted (70-79 years) and non-targeted age groups
21 (60-69 and 80-89 years) during January 2013-December 2018 was estimated using
22 interrupted time-series analyses.

23 *Results:* Prior to program commencement (Jan 2013 to Oct 2016) in patients aged
24 60-69, 70-79 and 80-89 years, incidence was mostly stable averaging respectively 7.2,
25 9.6 and 10.8 per 1000 person-years. In the two years following program
26 commencement, incidence fell steadily in those aged 70-79 years, with an estimated
27 decrease of 2.25 (95% CI: 1.34, 3.17) per 1000 person-years per year, with women
28 having a greater decrease than men (2.83 versus 1.68, p-interaction<0.01). In the two
29 non-vaccine-program-targeted age groups there was no evidence of reduction in
30 zoster incidence: 60-69 years, 0.46 (95% CI: -0.46, 1.38) and 80-89 years, 0.11 (95%
31 CI: -1.64, 1.87).

32 *Conclusions:* Two years after implementation, an estimated 7000 zoster cases were
33 prevented through the national program. With known waning vaccine efficacy,
34 continued surveillance is needed to ensure these early reductions in incidence are
35 sustained.

36

37 *Keywords:* Immunisation, herpes zoster, general practitioner, electronic medical
38 records

Introduction

Herpes zoster (zoster) is a painful rash that occurs following reactivation of the varicella zoster virus. It is more frequently observed in older people and those who are immunocompromised.¹ It can cause prolonged and severe pain leading to significant health problems including difficulty mobilising and also psychological conditions, such as anxiety, depression, and even social isolation.² The lifetime risk of acquiring zoster is 20-30%, with incidence increasing with age.^{3, 4} A recent study reported annual age-specific zoster incidence of 1.8 per 1000 persons for those aged under 25 years, 6.3 per 1000 for 50-59 year olds, and 19.9 per 1000 for those aged 80 years and over in Australia.⁵

Two effective zoster vaccines are currently registered; one is a live-attenuated vaccine with reported one-dose efficacy of 51.3% against zoster in adults aged 60 years and over⁶ and the other, a recombinant subunit adjuvanted vaccine with two-dose efficacy of 97.2% against zoster in adults aged 50 years and over⁷. In Australia, the live-attenuated vaccine was registered in 2007 but not available until 2013 by private prescription. The recombinant subunit adjuvanted vaccine was registered in 2018 but is not available yet. Since November 2016 in Australia under a National Herpes Zoster Immunisation Program, a single dose of the live-attenuated zoster vaccine has been offered to adults aged 70 years with a time-limited catch-up program for those aged 71-79 years until 2021.⁸ Evaluating the impact of this national program on zoster incidence has been limited by the fact that in Australia zoster is not notifiable in all states and territories,⁹ and the reliability of reporting of zoster to public health units is uncertain with notifications likely to underestimate true rates. Also, internationally there is only one other impact evaluation of a national zoster program.¹⁰

Therefore, in order to add to the limited knowledge regarding zoster vaccine program effects at a population level, the aim of this study was to evaluate the impact of the National Herpes Zoster Immunisation Program on zoster incidence by using a large national general practice dataset.

Methods

Ethics

70 This study was approved by the MedicineInsight Independent External Data
71 Governance Committee (reference number 2018-015) and the University of New
72 South Wales Human Research Ethics Committee (No. HC180939).

73

74 *Data source*

75 MedicineInsight is a large, longitudinal general practice dataset with data extracted
76 from electronic medical records in general practices across Australia. Participating
77 general practices consent to provide de-identified data on an ongoing basis to the
78 MedicineInsight program. The program was developed and is managed by NPS
79 MedicineWise. The dataset contains separate tables with patient demographic records,
80 diagnoses, reasons for encounter, and prescriptions made during patient encounters.
81 Each record is dated and is assigned a unique patient identifier. This enables records
82 related to the same individual to be linked. More details of this dataset are available
83 elsewhere.^{11, 12} In this study, we used an extract containing records from 25% of
84 patients randomly selected from the whole dataset with complete records to 31st
85 December 2018.

86

87 *Study population*

88 For this analysis we used presentations recorded in the MedicineInsight dataset
89 from 1st January 2013- 31st December 2018 in adults turning 60-89 years old. As
90 people in Australia have unrestricted choice when accessing general practice services,
91 we needed to define a regular attender for a population denominator to estimate
92 incidence. As done previously¹³, we defined our main study population as those who
93 had records of attending the same practice on at least one non-administrative visit
94 each year in the previous two years. Administrative visits were those that only
95 involved administrative notes, emails, faxes, file reviews, phone calls, and phone
96 messages. In addition, patients recorded as deceased in that year, or with missing data
97 on year of birth, sex or zoster diagnosis date were excluded from the study population.

98

99 *Definition of herpes zoster cases*

100 For our main analyses we defined a case as having a diagnosis of zoster if they had
 101 a term indicating zoster (zoster, HZ, shingles, zona) in either the encounter reason or
 102 diagnosis tables but not one of the exclusion terms. Exclusion terms included a word
 103 indicating only a possible/suspected diagnosis, or a term indicating the encounter was
 104 for vaccination, advice only, or related to a family member (see Appendix Table 1 for
 105 full list). Encounters where there was a record of a zoster vaccine administered in the
 106 immunisation table on the same date were also excluded as cases. As both the
 107 encounter reason and diagnosis tables were free text, to include possible misspellings,
 108 we used the SPEDIS function with cost ≤ 30 in SAS to identify closely related
 109 spellings to our zoster terms.

111 *Data analysis*

112 All records that met the case definition with the same patient identifier and record
 113 date were considered duplicates and removed before data analysis. If participants had
 114 more than one record of a zoster diagnosis over the study period, records that were
 115 separated by more than 180 days during the observation period were considered as
 116 distinct episodes of zoster¹⁴ and contributed to counts of events. For each calendar
 117 year of data, we divided participants into three groups based on the age they turned in
 118 that year: 60-69, 70-79 (targeted for vaccination), and 80-89 years old. Zoster
 119 incidence in each month and the year of observation was estimated by calculating the
 120 number of zoster episodes recorded in that period divided by person-years of the
 121 study population meeting the regular attender definition in that year.

122 For estimating annual zoster incidence before and after the national program, we
 123 separated data into the three-year time period from November 2013 to October 2016
 124 which was considered “before the program”, and the two-year period from November
 125 2016 to October 2018 which was considered “after the program”. We estimated zoster
 126 incidence in each period (before and after the program) and the relative and absolute
 127 reductions in incidence comparing the periods, stratified by age and sex. We also

128 calculated incidence before and after the program in those 70-79 years by practice
129 jurisdiction, remoteness status¹⁵ and area-level socioeconomic disadvantage using the
130 index of relative socioeconomic advantage and disadvantage (IRSAD)¹⁶.

131 We used an interrupted time-series model¹⁷ to further investigate the effect of the
132 national program on zoster incidence. We defined January 2013-October 2016 as the
133 pre-program period and November 2016-December 2018 as the post-program period.
134 A segmented regression was used, including terms to estimate the base level of
135 incidence at the beginning of the series, the pre-program trend in incidence, the
136 change in level of incidence immediately after the program and the change in trend of
137 incidence after the program. We assessed serial autocorrelation graphically and via
138 the Durbin-Watson statistic, accounting for autocorrelation where necessary by
139 including an auto-regressive term. Model assumptions were checked using graphical
140 summaries of residuals. In addition, we calculated the total number of zoster cases
141 averted in the vaccine-targeted age group in Australia by applying our estimates of
142 absolute reduction to population estimates from the 2016 census.¹⁸

143 All analyses were conducted with SAS v. 9.4 (SAS Institute Inc. Cary, North
144 Carolina, USA).

145

146 *Sensitivity analysis*

147 In the first sensitivity analysis we re-defined the study population, to be consistent
148 with the Royal Australian College of General Practitioners (RACGP)¹⁹ which defines
149 a regular attender as a patient who attended the same practice for at least three
150 non-administrative visits on different days within the last two years. For the second,
151 we broadened the definition of a zoster case by including those with a prescription
152 record of a zoster-specific antiviral (see Appendix Table 2 for details). This included
153 acyclovir (800 mg) with 35 tablets, valacyclovir (500 mg) with 42 tablets, or
154 famciclovir (250 mg) with 21 tablets.²⁰

155

156 **Results**

For each analysis year, there were: between 50814 and 62677 regular attenders aged 70-79 years, 82248 to 89542 aged 60-69 years, and 27166 to 29866 aged 80-89 years. For the vaccine-targeted age group (70-79 years), there were 2439 patients who met the zoster case definition over the five-year period, Nov 2013-Oct 2018. For the two non-vaccine-targeted age groups, 60-69 and 80-89 years of age, the corresponding figures were 1495 and 550, respectively.

Table 1 shows the crude average annual incidence of zoster before and after program commencement. Zoster incidence per 1000 person-years before and after the program was 9.5 versus 7.5 for those 70-79 years, 7.7 versus 8.3 for those 60-69 years and 9.0 versus 9.3 for those 80-89 years. Among those aged 70-79 years the absolute reduction in incidence was 2.0 per 1000 person-years or a relative reduction of 21%. Such falls were not observed in either the 60-69 or the 80-89 years age groups. Women had consistently higher incidence than men in all age groups both before and after program commencement and falls in incidence were observed for both men and women aged 70-79 years. Among the vaccine-targeted population (aged 70-79 years) we also found incidence decreased after the program in all remoteness and socioeconomic status categories, and in most jurisdictions, except the Northern Territory and Western Australia (Appendix Table 3).

Trends in zoster incidence pre- and post- program by age group are shown in Figure 1. Prior to program commencement in patients aged 60-69, 70-79 and 80-89 years, incidence was mostly stable averaging respectively 7.2, 9.6 and 10.8 per 1000 person-years. However, following the program commencement, the incidence fell steadily in those aged 70-79 years.

From the interrupted time-series analysis, the trend in zoster incidence in the vaccine-targeted age group decreased by 2.25 (95% CI: 1.34, 3.17) per 1000 person-years per year (Table 2). Women had a greater decrease than men (2.83 versus 1.68, test for interaction <0.01). By contrast, there was no evidence of reductions in zoster incidence trends for the two non-vaccine-targeted age groups.

186 *Sensitivity analyses*

187 Use of the RACGP definition of a regular attender did not change the patterns in
188 incidence. In those aged 70-79 years the post-program decrease in incidence was 1.98
189 (95% CI: 1.13, 2.84) per 1000 person-years per year whilst there was no change in
190 those 60-69 and those 80-89 years (see Appendix Table 4).

191 Using the broader zoster case definition resulted in higher incidences but the
192 patterns were similar. Before and after the program for those aged 60-69, 70-79,
193 80-89 years respectively: 9.4 versus 10.0, 11.5 versus 9.1, 11.0 versus 11.2 per 1000
194 person-years. There was also evidence of a reduction in incidence trends in the 70-79
195 years age group (reduction: 2.45 (95% CI: 1.63, 3.27) per 1000 person-years per year)
196 but not in either the 60-69 or the 80-89 years age groups (see Appendix Table 5).

197

198 **Discussion**

199 To the best of our knowledge, this is the first study to estimate the impact of the
200 National Zoster Immunisation Program on zoster incidence in Australia. We found
201 that in the two years after implementation, zoster incidence decreased by 2.25 per
202 1000 person-years per year or by about 40% from pre-program levels in the
203 vaccine-targeted population (those aged 70-79 years); no significant falls were
204 recorded in those aged 60-69 and 80-89 years.

205 Our findings are consistent with studies in other countries and regions that have
206 also implemented and evaluated zoster immunisation programs with live-attenuated
207 zoster vaccines. England introduced a zoster immunisation program for 70 year olds
208 with phased catch-up for those 71-79 years in September 2013.¹⁰ After three years,
209 vaccine coverage was reported as 60% in the vaccine-targeted population, and zoster
210 incidence was reported to decrease by 3.1 per 1000 person-years. In the Canadian
211 province of Ontario, a zoster immunisation program was introduced in September
212 2016 for adults aged 65-70 years.²¹ Results of a national survey showed vaccine
213 uptake was 21% among participants aged ≥ 50 years in 2016²² and the monthly

214 incidence of medically-attended zoster in the 2 years after program implementation
215 was reported to decrease by 1 per 10,000 population²¹.

216 Some of the differences in the estimated impact of the zoster immunisation
217 program in Australia compared to other regions could be due to differences in zoster
218 case ascertainment used in this study and vaccine coverage achieved. Estimates of
219 zoster vaccine uptake in Australia are limited. A report based on data from the
220 Australian Immunisation Register suggested that cumulative vaccine coverage 23
221 months after program commencement in Australia was 31.2% among adults aged
222 70-79 years but this is considered an underestimate due to underreporting.²³ Using
223 this same general practice database (MedicineInsight) in a separate study we have
224 estimated higher coverage (47%) in the targeted population 2 years after program
225 commencement.¹³

226 Women had both higher incidence of zoster but also greater reductions in incidence
227 than men following program implementation, and this might be explained by higher
228 vaccine uptake in women than men.^{13, 23} This sex difference was also observed in the
229 Canadian study.²¹ The fall in incidence post-program was also observed to be
230 relatively uniform across Australian regions (by remoteness) and socioeconomic
231 groups, and also in most jurisdictions, although not in the Northern Territory and
232 Western Australia. The lack of a reduction in incidence in the Northern Territory may
233 be due to the small number of participating practices in our sample and therefore a
234 lack of power to detect a difference; although vaccine coverage in the Northern
235 Territory is also reported to be substantially lower²³. The lack of change in incidence
236 detected in Western Australia is more difficult to explain as coverage is reportedly
237 similar to other jurisdictions²³ and further investigation is required to confirm this
238 difference.

239 Study strengths include the use of a large national general practice dataset of
240 electronic medical records allowing us sufficient numbers of cases in age groups to
241 investigate changes over time. However, there are some limitations. Firstly, we only
242 studied people attending GPs so zoster cases diagnosed in settings such as emergency

243 departments or hospitals or at GPs not participating in the MedicineInsight database
244 would be missed but this proportion is likely to be small and unlikely to differ
245 between the pre- and post-program periods examined. Secondly, there is the potential
246 for misclassification of zoster cases and we were unable to validate the case records.
247 However, we used the same case definition consistently over time and in different age
248 groups and we included a range of terms and misspellings to improve detection and
249 exclude questionable cases. The fact we observed a fall in incidence coinciding with
250 the time of program implementation and only in vaccine-targeted age groups suggest
251 that our definition was valid.

252

253 **Conclusion**

254 In summary, our study shows that the recently implemented National Herpes Zoster
255 Immunisation Program in Australia has had a significant impact on reducing zoster
256 incidence among the vaccine-targeted population and that the level of reduction
257 appears to be consistent with other regions in the world that have similar programs in
258 place, given differences in vaccine uptake. Based on Australian census data²⁴ for the
259 population aged 70-79 years (N=1,540,376), we estimate about 7000 zoster cases
260 would have been averted two years after the program commenced. Given the known
261 waning of vaccine efficacy for the live-attenuated vaccine,²⁵ longer-term evaluation of
262 this program is also needed to ensure that zoster incidence continues to decrease.

263

264 **Acknowledgements**

265 We thank the NPS MedicineWise MedicineInsight for providing the data for this
266 study. J. Lin is supported by the University International Postgraduate Awards under a
267 UNSW Tuition Fee Scholarship and a School of Population Health Stipend
268 Scholarship. B. Liu is supported by an NHMRC Fellowship.

269

270 **Declaration of Competing Interest**

271 None.

272 **References**

- 273 1. Arvin AM. Varicella-zoster virus. *Clin Microbiol Rev* 1996;**9**(3):361.
- 274 2. Lang P-O, Aspinall R. Vaccination in the Elderly: What Can Be Recommended? *Drugs*
- 275 & *Aging* 2014;**31**(8):581-99.
- 276 3. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?
- 277 *Lancet Infect Dis* 2004;**4**(1):26-33.
- 278 4. Schmader K. Herpes zoster in older adults. *Clin Infect Dis* 2001;**32**(10):1481-6.
- 279 5. MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing
- 280 trends of herpes zoster in Australia. *PLoS ONE* 2015;**10**(4):e0125025.
- 281 6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A
- 282 Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. *N Engl J*
- 283 *Med* 2005;**352**(22):2271-84.
- 284 7. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al.
- 285 Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. *N Engl J*
- 286 *Med* 2015;**372**(22):2087-96.
- 287 8. Australian Government Department of Health. National Immunisation Program Schedule.
- 288 2017 [cited 2020 5 June]. Available from:
- 289 [https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/nati](https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule)
- 290 [onal-immunisation-program-schedule](https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule).
- 291 9. Sheel M, Beard I F, Quinn II H, Dey A, Kirk M, Koehler A, et al. Australian vaccine
- 292 preventable disease epidemiological review series: varicella-zoster virus infections,
- 293 1998–2015. *J Commun Dis Intell* 2016;**40**(1):E189-E93.
- 294 10. Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, et al.
- 295 Evaluation of the effect of the herpes zoster vaccination programme 3 years after its
- 296 introduction in England: a population-based study. *Lancet Public Health*
- 297 2018;**3**(2):e82-e90.
- 298 11. NPS MedicineWise. MedicineInsight Data Book version 2.2. June 2019 [cited 2020 5
- 299 June]. Available from:
- 300 https://www.nps.org.au/assets/NPS/pdf/MedicineInsight_databook_June-2019.pdf.
- 301 12. Busingye D, Gianacas C, Pollack A, Chidwick K, Merrifield A, Norman S, et al. Data
- 302 Resource Profile: MedicineInsight, an Australian national primary health care database.
- 303 *Int J Epidemiol* 2019;**48**(6):1741–h.
- 304 13. Lin J, Wood JG, Bernardo C, Stocks NP, Liu B. Herpes zoster vaccine coverage in
- 305 Australia before and after introduction of a national vaccination program. *Vaccine*
- 306 2020;**38**(20):3646-52.
- 307 14. Donahue JG, Choo PW, Manson JE, Platt R. The Incidence of Herpes Zoster. *Arch*
- 308 *Intern Med* 1995;**155**(15):1605-9.
- 309 15. Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS). 2018
- 310 [cited 2020 5 June]. Available from:
- 311 [https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geograp](https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geography+Standard+(ASGS))
- 312 [hy+Standard+\(ASGS\)](https://www.abs.gov.au/websitedbs/D3310114.nsf/home/Australian+Statistical+Geography+Standard+(ASGS)).
- 313 16. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA) 2016. March
- 314 2018 [cited 2020 5 June]. Available from:

- 315 <https://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/756EE3DBEFA869EFCA258>
- 316 [259000BA746/\\$File/SEIFA%202016%20Technical%20Paper.pdf](https://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/756EE3DBEFA869EFCA258259000BA746/$File/SEIFA%202016%20Technical%20Paper.pdf).
- 317 17. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of
- 318 interrupted time series studies in medication use research. *J Clin Pharm Ther*
- 319 2002;**27**(4):299-309.
- 320 18. Australian Bureau of Statistics. 2016 Census. 2017 [cited 2020 5 June]. Available from:
- 321 <https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/Assuring%20Census%20Data>
- 322 [%20Quality](https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/Assuring%20Census%20Data%20Quality).
- 323 19. The Royal Australian College of General Practitioners. Standards for general practices
- 324 (4th edition). 2015 [cited 2020 5 June]. Available from:
- 325 <https://www.racgp.org.au/download/documents/Standards/standards4thedition.pdf>.
- 326 20. Liu B, Heywood AE, Reekie J, Banks E, Kaldor JM, McIntyre P, et al. Risk factors for
- 327 herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study.
- 328 *Epidemiol Infect* 2015;**143**(13):2871-81.
- 329 21. Martins D, McCormack D, Tadrous M, Gomes T, Kwong JC, Mamdani MM, et al.
- 330 Impact of a publicly funded herpes zoster immunization program on the burden of
- 331 disease in Ontario, Canada: a population-based study. [published online ahead of print,
- 332 2020 Jan 10]. *Clin Infect Dis* 2020:ciaa014. doi: 10.1093/cid/ciaa014.
- 333 22. Public Health Agency of Canada. Vaccine uptake in Canadian adults : results from the
- 334 2016 Adult National Immunization Coverage Survey (aNICS). 2018 [cited 2020 5 June].
- 335 Available from:
- 336 http://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-222-2018-eng.pdf.
- 337 23. National Centre for Immunisation Research and Surveillance. Exploratory analysis of the
- 338 first 2 years of adult vaccination data recorded on AIR. 2019 [cited 2020 5 June].
- 339 Available from:
- 340 [http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%](http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf)
- 341 [20data%20on%20AIR_Nov%202019.pdf](http://ncirs.org.au/sites/default/files/2019-12/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf).
- 342 24. Australian Bureau of Statistics. Patient Experiences in Australia: Summary of Findings,
- 343 2017-18. 2018 [cited 2020 5 June]. Available from:
- 344 [https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocum](https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocument)
- 345 [ent](https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4839.02017-18?OpenDocument).
- 346 25. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al.
- 347 Long-term persistence of zoster vaccine efficacy. *Clin Infect Dis* 2015;**60**(6):900-9.

348

349 **Table 1** Crude annual incidence of herpes zoster per 1000 person-years before and
 350 after implementation of the National Herpes Zoster Immunisation Program among
 351 patients attending General Practices in Australia, by age and sex.

Age, sex	Before program (Nov 2013-Oct 2016)	After program (Nov 2016-Oct 2018)
60-69 y		
Overall	7.7 (1979/256157)	8.3 (1495/179146)
Men	6.3 (753/119315)	6.6 (547/82576)
Women	9.0 (1226/136842)	9.8 (948/96570)
70-79 y		
Overall	9.5 (1518/160727)	7.5 (921/122779)
Men	8.4 (626/74847)	6.6 (381/57692)
Women	10.4 (892/85880)	8.3 (540/65087)
80-89 y		
Overall	9.0 (756/83874)	9.3 (550/59234)
Men	7.7 (272/35392)	8.9 (224/25130)
Women	10.0 (484/48482)	9.6 (326/34104)

352 Incidence is shown by the incidence rate (total number of zoster episodes/total number of
 353 person-years).

Table 2 Impact of the National Herpes Zoster Immunisation Program on trends in incidence of herpes zoster among patients attending General Practices in Australia, by age and sex.

Age, sex	Pre-program trend ^a	Post-program trend ^b	Change in trend	
			Estimate (95% CI)	P-value
60-69 y				
Overall	0.18 (-0.23, 0.59)	-0.28 (-1.05, 0.50)	-0.46 (-1.38, 0.46)	0.3
Men	-0.08 (-0.45, 0.29)	-0.20 (-1.17, 0.78)	-0.12 (-1.13, 0.88)	0.8
Women	0.22 (-0.35, 0.80)	-0.59 (-1.78, 0.61)	-0.81 (-2.19, 0.57)	0.3
70-79 y				
Overall	0.09 (-0.31, 0.48)	-2.16 (-2.94, -1.40)	-2.25 (-3.17, -1.34)	<0.001
Men	-0.09 (-0.53, 0.35)	-1.77 (-2.93, -0.62)	-1.68 (-2.87, -0.49)	<0.001
Women	0.06 (-0.50, 0.62)	-2.77 (-4.09, -1.45)	-2.83 (-4.26, -1.40)	<0.001
80-89 y				
Overall	-0.13 (-0.89, 0.62)	-0.25 (-1.75, 1.26)	-0.11 (-1.87, 1.64)	0.9
Men	-0.27 (-1.20, 0.66)	-0.16 (-2.12, 1.82)	0.11 (-2.12, 2.35)	0.9
Women	-0.08 (-1.04, 0.89)	-0.67 (-2.93, 1.60)	-0.59 (-3.05, 1.87)	0.6

CI, incidence interval.

^a Pre-program trend (per 1000 person-years per year) is calculated over Jan 2013-Oct 2016 and shown by estimate (95% CI).

^b Post-program trend (per 1000 person-years per year) is calculated over Nov 2016- Dec 2018 and shown by estimate (95% CI).

362 **Figure legend**

363 **Fig. 1.** Monthly incidence of herpes zoster per 1000 person-years among patients aged

364 (A) 60-69, (B) 70-79 and (C) 80-89 years old attending General Practices during Jan

365 2013-Dec 2018 in Australia.